Clinical Policy Bulletin:
Total Body Photography and Dermoscopy

Revised February 2015

Number: 0188

Policy

I. Aetna considers total body photography (TBP) and dermoscopy (also known as digital epiluminescence microscopy (DELM), epiluminescence microscopy [ELM], incidence light microscopy, skin videomicroscopy, melanomography, in-vivo cutaneous surface microscopy, dermatoscopy, and magnified oil immersion discoscopy) medically necessary when used for evaluation of members with a history or close family history of any of the following conditions:

A. Atypical nevi; or
B. Dysplastic nevi; or
C. Melanoma.

Repeat studies are not typically required more frequently than every 24 months.

Aetna considers TBP and dermoscopy experimental and investigational for all other indications because their effectiveness for indications other than the ones listed above has not been established.

II. Aetna considers computerized TBP systems (e.g., MelaFind, MoleMapCD, MoleMate, MoleSafe) experimental and investigational because they have not been shown to provide better health outcomes than conventional TBP.

III. Aetna considers the following approaches (not an all-inclusive list) experimental and investigational for detecting and monitoring dysplastic and atypical nevi for early detection of malignant cutaneous melanomas because their clinical value for this indication has not been established.

Confocal scanning laser microscopy
Electrical impedance devices
High-resolution ultrasonography
Multi-photon laser scanning microscopy (also known as multi-photon fluorescence microscopy or multi-photon excitation microscopy)
Multi-spectral image analysis Optical coherence tomography Reflectance confocal microscopy (RCM)
Spectroscopy (impedance and optical)
Visual image analysis

Background

Total body photography (TBP) and dermoscopy (also known as digital epiluminescence microscopy (DELM), epiluminescence microscopy [ELM], incidence light microscopy, skin videomicroscopy, melanomography, in-vivo cutaneous surface microscopy, dermatoscopy, and magnified oil immersion diascopy) are established techniques for detecting and monitoring dysplastic and atypical nevi for early detection of malignant cutaneous melanomas.

The fact that dysplastic and atypical nevi may appear as potential precursors of cutaneous malignant melanoma (CMM) has made possible early identification of individuals who are at increased risk for developing CMM. Moreover, there is ample evidence that early resection of malignant melanoma is associated with an excellent prognosis. Thus, it is important that individuals with dysplastic or atypical nevi receive regular cutaneous examination to identify new and changing nevi. Total body photography is helpful for patients with numerous nevi, to identify changes in these lesions during regular examinations.

A dermoscope (e.g., MoleMax II™) is a specialized microscope that is used for in vivo examination of pigmented skin lesions, in order to distinguish melanocytic from non-melanocytic pigmented lesions and determine whether melanocytic pigmented lesions are likely to be malignant. Even though most malignant melanocytic lesions can be identified on the basis of unaided visual inspection alone, there are many lesions that are not readily distinguished by examination with the naked eye.

The dermoscope can also be used to visualize the subsurface layers of the skin. With the addition of the oil immersion technique, the epidermis becomes translucent, permitting macroscopic evaluation of the dermo-epidermal junction. Most studies have shown that this method improves diagnostic accuracy of pigmented skin lesions by 20 % to 30 % with respect to simple clinical observation, especially by an expert dermatologist.

Since its introduction, dermoscopy has undergone extensive improvements; the instruments have become more readily available; and the diagnostic indications, benefits, and limitations have been better delineated. Dermoscopy has developed into a powerful tool to discriminate between melanocytic and non-melanocytic pigmented skin lesions, and to distinguish benign from malignant melanocytic lesions in order to avoid inopportune surgical treatments for low risk lesions. Although dermoscopy does not show 100 % sensitivity in diagnosing CMM, it is more accurate than un-aided visual inspection in detecting thin CMM. Features of pigmented lesions identified by dermoscopy should be integrated with data from the history and physical examination.

The recent advent of digital imaging systems for acquiring and archiving total body skin images has resulted in greater dissemination of this technique. Although computer-based systems supposedly will provide sophisticated functionalities for automated feature extraction and lesion assessment for quantitative analysis, there is a need to better standardize computerized TBP systems if they are going to be used more extensively.

There is insufficient evidence that computerized TBP systems such as MoleMapCD provide better health outcomes than conventional TBP. In this regard, Schindewolf et al (1994) ascertained if conventional color slides or directly digitized images should be used for a reliable recognition of malignant melanoma. The authors concluded that both image acquisition techniques allow a reliable detection of malignant
melanoma and both are appropriate as input for an image analysis system regarding its efficiency as a diagnostic tool. Furthermore, Brown (2002) examined the various diagnostic techniques for melanoma. A total of 6 general categories dealing with diagnostic techniques for melanoma were identified: (i) naked-eye clinical examination alone, (ii) clinical examination with the aid of TBP, (iii) epiluminescence microscopy (ELM), (iv) digital ELM, (v) computer-assisted techniques, and (vi) teledermatology. Because of the research citing the poor diagnostic accuracy (DA) of non-dermatologists, increased DA with dermatologists experienced in ELM techniques, and the importance of early melanoma diagnosis, the recommendation is to refer patients with suspicious pigmented skin lesions to experienced dermatologists, preferably those who use ELM or digital ELM.

In a review on skin imaging, Rallan and Harland (2004) stated that mole scanners are increasingly available on a commercial basis even though computer diagnosis of pigmented lesions is currently no better than diagnosis by human experts, and other imaging techniques, such as high-resolution ultrasonography, spectroscopy and optical coherence tomography, may yet find a role in diagnosis and disease monitoring.

Starritt et al (2005) stated that the value of targeted high-resolution ultrasound (US) examination in detecting sentinel lymph node (SLN) metastases in patients with newly diagnosed primary cutaneous melanomas has not yet been fully evaluated. These investigators examined the threshold size of metastatic melanoma deposits in SLNs that are able to be detected by targeted US examination before initial melanoma surgery (n = 304). Metastatic disease was present in SLNs from 33 node fields in 31 patients. The US results in 7 of these cases were suggestive of metastatic disease; 26 node fields contained positive nodes not detected by US. Undetected deposits had diameters that are less than 4.5 mm. These researchers concluded that the findings of this study suggest that a targeted US examination of SLNs can detect metastatic melanoma deposits down to approximately 4.5 mm in diameter. They further noted that, however, most metastatic melanoma deposits in SLNs are considerably smaller than this at the time of initial staging, thus targeted high-resolution ultrasound cannot be considered cost-effective in this setting.

Gerger et al (2005) stated that in vivo confocal laser scanning microscopy (CLSM) represents a novel imaging tool that allows the examination of skin morphology in real time at a resolution equal to that of conventional microscopes. These researchers tested the applicability of CLSM to the diagnostic discrimination of benign nevi and melanoma. Five independent observers without previous experience in CLSM received a standardized instruction about diagnostic CLSM features. Subsequently, 117 melanocytic skin tumors (90 benign nevi and 27 melanoma), imaged using a commercially available, near-infrared, reflectance confocal laser scanning microscope, were evaluated by each observer. Overall, sensitivity of 88.2 % and specificity of 97.6 % was achieved by the 5 observers. Logistic regression analysis revealed that mainly cytomorphology, architecture and keratinocyte cell borders should be taken into account for diagnostic decisions. Remarkably, using the presence or absence of monomorphic melanocytes as a single diagnostic criterion, the classification results with a sensitivity of 98.2 % and a specificity of 98.9 % were superior to the intuitive, integrative judgment of the observers. These investigators concluded that this first sensitivity and specificity study with CLSM has yielded promising results. Furthermore, Marghoob and Halpern (2005) stated that the future of CLSM looks bright; however, much work is needed before the application of this technology in routine clinical practice.

Gerger et al (2006) noted that in vivo CLSM examination appeared to be a promising method for the non-invasive assessment of melanoma and non-melanoma skin tumors. This is in agreement with the observation of Menzies (2006), who stated that the use of automated instruments for the diagnosis of cutaneous melanoma is still in an experimental phase, and its utility is dependent on the evidence that
such instruments give a clinically useful expert second opinion. Currently, other non-invasive diagnostic techniques such as in vivo CLSM are reserved for clinical research settings.

Gerger and colleagues (2009) stated that in vivo confocal microscopy represents a novel imaging tool that allows the non-invasive examination of skin cancer morphology in real time at a “quasi-histopathological” resolution viewing micro-anatomical structures and individual cells. Numerous morphological confocal features of melanocytic skin tumors have been described and histopathological correlates of confocal structures have been previously elucidated. Recently, several studies have evaluated the diagnostic accuracy of in vivo confocal microscopy for melanocytic skin tumors, investigating approximately 50,000 tumor images. Remarkably, sensitivity superior to the diagnostic accuracy achieved with dermoscopy could be reached by this imaging modality. These studies represented a significant contribution to the body of research necessary for the evaluation and implementation of in vivo confocal microscopy in clinical practice to avoid many currently unnecessary biopsies. In vivo confocal microscopy probably augurs a sea change in the way melanocytic skin tumors are evaluated in the future and will ultimately move the art of histological diagnosis closer to the bedside.

Psaty and Halpern (2009) noted that diagnostic aids such as TBP and dermoscopy, improve clinicians’ ability to diagnose melanoma beyond un-aided visual inspection, and are considered mainstream methods for early detection. Emerging technologies such as in vivo reflectance confocal microscopy are currently being investigated to determine their utility for non-invasive diagnosis of melanoma.

Sanki et al (2009) re-assessed traditional ultrasound descriptors of SLN metastases to (i) determine the minimum cross-sectional area (CSA) of an SLN metastasis detectable by US, and (ii) establish whether targeted, high-resolution US of SLNs identified by lymphoscintigraphy before initial melanoma surgery can be used as a substitute for excisional SLN biopsy. High-resolution US was performed on SLNs identified in 871 lymph node fields in 716 patients; SLN biopsy was performed within 24 hours of lymphoscintigraphy and US examination. The CSA of each SLN metastatic deposit was determined sonographically and histologically. The sensitivity of targeted US in the detection of positive SLNs was 24.3 % (95 % confidence interval [CI]: 19.5 % to 28.7 %), and the specificity was 96.8 % (95 % CI: 95.9 % to 97.7 %). The sensitivity was highest for neck SLNs (45.8 %) and improved with greater Breslow thickness. The median histologic CSA of the SLN metastatic deposits was 0.39 mm² (12.75 mm²) for US true-positive results and 0.22 mm² (for US false-negative results). True-positive, US-detected SLNs had significantly greater CSAs (t-test p < 0.001) than undetected SLN metastases and were more likely to be spherical in cross-section. More than 2 sonographic descriptors of SLN metastases or rounding of the node alone were factors highly suggestive of a melanoma deposit. The authors concluded that high-resolution US is not an appropriate substitute for SLN biopsy, but it is of value in pre-operative SLN assessment and post-operative monitoring. These findings are in agreement with those of Kunte et al (2009) who reported that high resolution B-mode US can not replace SLN biopsy, especially in the detection of micro-metastases, but it remains the most important method to assess the lymph node status for macrometastases pre-surgically.

Glud et al (2009) noted that dermoscopy is considered to be the gold standard for the clinical assessment of pigmented skin lesions. In expert hands, this instrument improves both sensitivity and specificity for the diagnosis of melanoma, however, the outcome is highly dependent on the skills and experience of the examiner. Spectrophotometric intra-cutaneous analysis (SIAscopy) is a new, commercially available method of analyzing pigmented skin lesions non-invasively. The diagnosis is based on objective features such as the presence of dermal pigment, vascularity of the lesion, and the integrity of collagen. These researchers examined the usefulness of SIAscopy for the clinical diagnosis of malignant melanoma in a prospective, unbiased manner. They enrolled 65 patients with 83 lesions, where the diagnosis of melanoma could not be ruled out on the basis of the clinical evaluation by a non-dermatologist. All lesions were investigated by dermoscopy and SIAscopy and subsequently excised.
Histopathologically, 12 lesions were diagnosed as malignant melanoma. Both dermoscopy and SIAscopy over-estimated the proportion of possible malignant lesions (n = 24 and n = 41, respectively) and had sensitivities of 92 % and 100 %, respectively. The specificity of dermoscopy in this study was 81 % against 59 % for SIAscopy. These findings showed that dermoscopy remains the best diagnostic tool for the pre-operative diagnosis of pigmented skin lesions.

An Agency for Healthcare Research and Quality's Technical Brief on "Noninvasive diagnostic techniques for the detection of skin cancers" (Parsons et al, 2011) stated that multi-photon laser scanning microscopy (also known as multi-photon fluorescence microscopy or multi-photon excitation microscopy) uses more than 1 photon excitation to illuminate endogenous fluorophores in skin tissues, which emits a fluorescence signal to be captured by a detector. Similar to CSLM, multi-photon laser scanning microscopy uses laser beam and allows imaging of tissues beyond the superficial epidermis. Unlike CSLM, this technique does not use a confocal pinhole filter. Evidence of the current application of this modality is sparse. Systematic literature search identified 3 narrative reviews and 2 diagnostic studies of multi-photon microscopy or tomography. These investigators identified 2 registered cross-sectional studies that assess the use of this technology for skin lesion evaluation. Both studies are based in Taiwan and are recruiting participants. The only commercially available device for multi-photon tomography is DermalInspect, manufactured by JenLab in Germany. The authors could not determine the FDA clearance status for this device on the FDA CDRH database; and listed multi-photon laser scanning microscopy as one of the investigational devices for the detection of skin cancers.

Marchesini et al (2002) noted that early detection and prompt excision of cutaneous melanoma is of paramount importance to improve patient survival, and the clinician should be aware of the clinical features that suggest the presence of a malignant lesion. The clinical diagnosis is mainly based on observation of the color and shape of a given skin lesion. Unfortunately, evaluation of a pigmented lesion is to a large extent subjective and is closely related to the experience of the clinician. To overcome this problem, optical imaging techniques using different instrumentation (i.e., color video camera, ELM, reflectance spectrophotometry [SPT]) and computer image analysis have been proposed in an attempt to provide quantitative measurements in an objective and reproducible fashion. The different procedures employed to perform the diagnosis automatically all have a common denominator: mimicking the eye and the brain of the clinician by image processing and computerized analysis programs, respectively. Sensitivity and specificity data reported in the literature suggest that the computer-based diagnosis of melanoma does not greatly differ from the diagnostic capability of an expert clinician, and is independent of the optical acquisition method employed to analyze the lesions. Most of the computer-processed morphometric variables useful in automated diagnosis are not recognizable nor can be objectively evaluated by the human eye, except that of lesion dimension. However, several questions should be answered before assessing the actual usefulness, including the potential and limitations, of computer-based diagnostic procedures.

Glud et al (2009) stated that spectrophotometric intra-cutaneous analysis (SIAscopy) is a new, commercially available method of analyzing pigmented skin lesions non-invasively. The diagnosis is based on objective features such as the presence of dermal pigment, vascularity of the lesion, and the integrity of collagen. The objective of this study was to examine the usefulness of SIAscopy for the clinical diagnosis of malignant melanoma in a prospective, unbiased manner. These investigators enrolled 65 patients with 83 lesions, where the diagnosis of melanoma could not be ruled out on the basis of the clinical evaluation by a non-dermatologist. All lesions were investigated by dermoscopy and SIAscopy and subsequently excised. Histopathologically, 12 lesions were diagnosed as malignant melanoma. Both dermoscopy and SIAscopy over-estimated the proportion of possible malignant lesions (n = 24 and 41, respectively) and had sensitivities of 92 and 100 %, respectively. The specificity of dermoscopy in this study was 81 % against 59 % for SIAscopy. These findings showed that dermoscopy remains the best diagnostic tool for the pre-operative diagnosis of pigmented skin lesions. However, as
the SIAscope in addition to the SIAgaph images produces dermoscopic images, it holds the advantages in training and archiving.

Ascierto et al (2010) stated that SPT could represent a promising technique for the diagnosis of cutaneous melanoma (CM) at earlier stages of the disease. These investigators evaluated the role of SPT in CM early detection. During a health campaign for malignant melanoma at National Cancer Institute of Naples, these researchers identified a subset of 54 lesions to be addressed to surgical excision and histological examination. Before surgery, all patients were investigated by clinical and ELM screenings; selected lesions underwent SPT analysis. For SPT, these investigators used a video SPT imaging system (Spectroshade MHT S.p.A., Verona, Italy). Among the 54 patients harboring cutaneous pigmented lesions, these researchers performed comparison between results from the SPT screening and the histological diagnoses as well as evaluation of both sensitivity and specificity in detecting CM using either SPT or conventional approaches. For all pigmented lesions, agreement between histology and SPT classification was 57.4 %. The sensitivity and specificity of SPT in detecting melanoma were 66.6 % and 76.2 %, respectively. The authors concluded that although SPT is still considered as a valuable diagnostic tool for CM, its low accuracy, sensitivity, and specificity represent the main hamper for the introduction of such a methodology in clinical practice. Dermoscopy remains the best diagnostic tool for the pre-operative diagnosis of pigmented skin lesions.

Smith and Macnell (2011) discussed recent developments in the non-invasive imaging of skin, in particular at how such imaging may be used at present or in the future to detect CM. A Medline search was performed for articles using imaging techniques to evaluate CM, including melanoma metastasis. A total of 9 different techniques were found: dermoscopy, confocal laser scanning microscopy (including multi-photon microscopy), optical coherence tomography, high-frequency ultrasound, positron emission tomography, magnetic resonance imaging, and Fourier, Raman, and photo-acoustic spectroscopies. The authors concluded that despite the variety of techniques available for detecting melanoma, there remains a critical need for a high-resolution technique to answer the question of whether tumors have invaded through the basement membrane.

In a prospective, multi-center, blinded study, Monheit et al (2011) examined the safety and effectiveness of MelaFind, a non-invasive and objective computer-vision system designed to aid in detection of early pigmented cutaneous melanoma. The diagnostic performance of MelaFind and of study clinicians was evaluated using the histologic reference standard. Standard images and patient information for a subset of 50 randomly selected lesions (25 melanomas) were used in a reader study of 39 independent dermatologists to estimate clinicians’ biopsy sensitivity to melanoma. A total of 1,383 patients with 1,831 lesions enrolled from January 2007 to July 2008; 1,632 lesions (including 127 melanomas – 45 % in situ with median Breslow thickness of invasive lesions, 0.36 mm) were eligible and evaluable for the study end points. Main outcome measures included sensitivity of MelaFind; specificities and biopsy ratios for MelaFind and the study investigators; and biopsy sensitivities of independent dermatologists in the reader study. The measured sensitivity of MelaFind was 98.4 % (125 of 127 melanomas) with a 95 % lower confidence bound at 95.6 % and a biopsy ratio of 10.8:1; the average biopsy sensitivity of dermatologists was 78 % in the reader study. Including borderline lesions (high-grade dysplastic nevi, atypical melanocytic proliferations, or hyperplasias), MelaFind’s sensitivity was 98.3 % (172 of 175), with a biopsy ratio of 7.6:1. On lesions biopsied mostly to rule out melanoma, MelaFind’s average specificity (9.9 %) was superior to that of clinicians (3.7 %) (p = 0.02). The authors concluded that MelaFind is a safe and effective tool to assist in the evaluation of pigmented skin lesions. However, it is unclear if an instrument with such a low specificity is clinically useful.

In a randomized, controlled trial, Walter et al (2012) examined if adding a novel computerized diagnostic tool, the MoleMate system (SIAscopy with primary care scoring algorithm), to current best practice results in more appropriate referrals of suspicious pigmented lesions to secondary care, and to assess
its impact on clinicians and patients. Subjects were 1,297 adults with pigmented skin lesions not immediately diagnosed as benign. Patients were assessed by trained primary care clinicians using best practice (clinical history, naked eye examination, 7-point checklist) either alone (control group) or with the MoleMate system (intervention group). Main outcome measures included appropriateness of referral, defined as the proportion of referred lesions that were biopsied or monitored. Secondary outcomes related to the clinicians (diagnostic performance, confidence, learning effects) and patients (satisfaction, anxiety). Economic evaluation, diagnostic performance of the 7-point checklist, and 5-year follow-up of melanoma incidence were also secondary outcomes and will be reported later. A total of 1,297 participants with 1,580 lesions were randomized: 643 participants with 788 lesions to the intervention group and 654 participants with 792 lesions to the control group. The appropriateness of referral did not differ significantly between the intervention or control groups: 56.8 % (130/229) versus 64.5 % (111/172); difference -8.1 % (95 % CI: -18.0 % to 1.8 %). The proportion of benign lesions appropriately managed in primary care did not differ (intervention 99.6 % versus control 99.2 %, p = 0.46), neither did the percentage agreement with an expert decision to biopsy or monitor (intervention 98.5 % versus control 95.7 %, p = 0.26). The percentage agreement with expert assessment that the lesion was benign was significantly lower with MoleMate (intervention 84.4 % versus control 90.6 %, p < 0.001), and a higher proportion of lesions were referred (intervention 29.8 % versus control 22.4 %, p = 0.001). A total of 36 histologically confirmed melanomas were diagnosed: 18/18 were appropriately referred in the intervention group and 17/18 in the control group. Clinicians in both groups were confident, and there was no evidence of learning effects, and therefore contamination, between groups. Patients in the intervention group ranked their consultations higher for thoroughness and reassuring care, although anxiety scores were similar between the groups. The authors concluded that there was no evidence that the MoleMate system improved appropriateness of referral. The systematic application of best practice guidelines alone was more accurate than the MoleMate system, and both performed better than reports of current practice. Therefore, the systematic application of best practice guidelines (including the s7-point checklist) should be the paradigm for management of suspicious skin lesions in primary care.

Longo et al (2013) stated that reflectance confocal microscopy (RCM) is a novel technique that allows visualization of the skin at nearly histological resolution although limited laser depth penetration hampers visualization of the deep dermis. These researchers examined if the diagnostic accuracy of RCM was comparable to histopathology for the diagnosis of nodular lesions, and identified possible limitations of this technique. They retrospectively evaluated 140 nodules by means of RCM while blinded from the histopathological diagnosis. At the end of the study the patient codes were broken and the evaluations were matched with histopathological diagnosis before performing statistical analysis. The study consisted of 140 nodular lesions (23 “pure” nodular melanomas, 9 melanoma metastases, 28 BCCs, 6 invasive SCCs, 32 naevi, 14 seborrheic keratoses, 17 dermatofibromas, 5 vascular lesions and 6 other lesions). Reflectance confocal microscopy correctly diagnosed 121 of 140 lesions (86.4 %); 8 of 140 (5.7 %) lesions revealed discordance between histopathology and confocal microscopy. Eight of the 140 (5.7 %) cases were not evaluable by means of RCM due to the presence of ulceration or hyperkeratosis and 3 cases showed a non-specific pattern. Interestingly, confocal microscopy reached a 96.5 % sensitivity and 94.1 % specificity (area under curve 0.970) (95 % CI: 0.924 to 1.015) (p < 0.001) for the diagnosis of melanoma. The authors concluded that this study was retrospective and lesions were not included on the basis of their diagnostic difficulty. They noted that despite the limited laser depth penetration of RCM, this imaging tool represents an effective instrument in diagnosing nodular lesions; however, for fully ulcerated lesions or when a marked hyperkeratosis is present, biopsy should always be performed. They stated that prospective studies on difficult-to-diagnose nodules should be performed to analyze further the pros and cons of RCM in skin cancer diagnosis.

Mohr et al (2013) stated that previous studies have shown statistically significant differences in electrical impedance between various cutaneous lesions. Electrical impedance spectroscopy (EIS) may therefore
be able to aid clinicians in differentiating between benign and malignant skin lesions. These researchers developed a classification algorithm to distinguish between melanoma and benign lesions of the skin with a sensitivity of at least 98 % and a specificity of approximately 20 % higher than the diagnostic accuracy of dermatologists. A total of 1,300 lesions were collected in a multi-center, prospective, non-randomized clinical trial from 19 centers around Europe. All lesions were excised and subsequently evaluated independently by a panel of 3 expert dermatopathologists. From the data 2 classification algorithms were developed and verified. For the first classification algorithm, approximately 40 % of the data were used for calibration and 60 % for testing. The observed sensitivity for melanoma was 98.1 % (101/103), non-melanoma skin cancer 100 % (25/25) and dysplastic nevus with severe atypia 84.2 % (32/38). The overall observed specificity was 23.6 % (66/280). For the second classification algorithm, approximately 55 % of the data were used for calibration. The observed sensitivity for melanoma was 99.4 % (161/162), for non-melanoma skin cancer was 98.0 % (49/50) and dysplastic nevus with severe atypia was 93.8 % (60/64). The overall observed specificity was 24.5 % (116/474). The authors concluded that EIS has the potential to be an adjunct diagnostic tool to help clinicians differentiate between benign and malignant (melanocytic and non-melanocytic) skin lesions. They stated that further studies are needed to confirm the validity of the automatic assessment algorithm.

CPT Codes / HCPCS Codes / ICD-9 Codes

CPT codes covered if selection criteria are met:

96904 Whole body integumentary photography, for monitoring of high-risk patients with dysplastic nevus syndrome or a history of dysplastic nevi, or patients with a personal or family history of melanoma

CPT codes not covered for indications listed in the CPB:

Confocal Scanning Laser Microscopy (No Specific Code):

Electrical impedance devices (No Specific Code):

High-resolution ultrasonography (No Specific Code):

Multi-photon laser scanning microscopy (also known as multi-photon fluorescence microscopy or multi-photon excitation microscopy) (No Specific Code):


Spectroscopy (No Specific Code):

Visual image analysis (No Specific Code):

ICD-9 codes covered if selection criteria are met:

172.0 - 172.9 Malignant melanoma of the skin [not covered for multi-photon laer scanning microscopy]

V10.82 Personal history of malignant melanoma of skin
Other ICD-9 codes related to the CPB:

216.0 - 216.9  Benign neoplasm of skin

The above policy is based on the following references:


48. Parrella A. Solar Scan for diagnosis and monitoring of melanoma. Horizon Scanning Prioritization Summary -- Volume 8. Adelaide, SA: Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC); February 2005;8(1).


